ClinicalTrials.gg
CompletedNCT05500586Updated Nov 4, 2026Results posted

The Effects of Glucagon on Hepatic Metabolism

A Phase 1/2 interventional study of Glucagon response study in Obesity, Type2diabetes and NAFLD, sponsored by Adrian Vella. Completed at 1 site in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Adrian Vella · Phase 1/2, Interventional, and Basic science

How we know

Updated Oct 14, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
25 Years to 65 Years
Sex
All
01

Study summary

Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important, unanswered questions. NAFLD is associated with T2DM risk and impaired insulin action. Unfortunately, it is unclear if glucagon resistance is caused by obesity, hepatic steatosis or both. The experiments outlined will determine if glucagon's actions on hepatic amino acid catabolism and EGP interact with hepatic lipid metabolism in lean and obese subjects with and without T2DM (and with varying degrees of hepatic steatosis).

Read the detailed description

T2DM and prediabetes are characterized by abnormal post-prandial suppression of glucagon, which contributes to postprandial hyperglycemia by increasing EGP. Although these effects are magnified by decreased and delayed insulin secretion, they are also apparent when insulin secretion is intact. In rodents, altered glucagon signaling changes α-cell function and mass - an effect mediated by changes in circulating AA concentrations. Are the elevated concentrations of branched-chain AA and other AA metabolites in T2DM a cause or an effect of global α-cell dysfunction? Could altered glucagon signaling precipitate a vicious cycle resulting in T2DM?

02

Conditions studied

  • Obesity
  • Type2diabetes
  • NAFLD

Keywords

  • glucagon
  • insulin resistance
  • hepatic steatosis
  • amino acid metabolism
03

In context

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's enrollment of 21 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Adrian Vella is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria - Obese Subjects with Type 2 Diabetes:

  • Type 2 diabetes
  • ≥ 28 Kg/M2
  • Managed by diet alone or a combination of metformin and/or sulfonylurea
  • Willing to stop glucose-lowering medication for 3 weeks prior to participation and willing to self-monitor their fasting glucose during this time
  • No history of micro- or macrovascular complications of T2DM

Exclusion Criteria - Obese Subjects with Type 2 Diabetes:

  • Age \< 25 or > 65 years
  • ≥ 8.5%
  • BMI ≤ 28 Kg/M2
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or .
  • Symptomatic macrovascular or microvascular disease.
  • Known to MRI
  • Hematocrit \< 35%
  • History of uncontrolled thyroid disease
  • Consumption of > 2 alcohol drinks per day or > 14 per week or a positive AUDIT questionnaire.
  • Allergy to iodine
  • Thrombocytopenia, history of bleeding disorder or use of anticoagulation
  • Subjects with treatment change or significant weight change (≥ 10%) in the prior 3 months.

Inclusion Criteria - Obese subjects without Type 2 Diabetes:

-Obese subjects without type 2 diabetes but are age, sex and weight-matched (BMI ≥ 28 Kg/M2) with subjects who have T2DM

Exclusion Criteria - Obese Subjects without Type 2 Diabetes:

  • Age \< 25 or > 65 years (match subjects with T2DM)
  • HbA1c ≥ 6.5%
  • BMI ≤ 28 Kg/M2
  • Use of any glucose-lowering agents
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.
  • Known contraindications to MRI
  • Hematocrit \< 35%
  • History of uncontrolled thyroid disease.
  • Consumption of > 2 alcohol drinks per day or > 14 per week or a positive AUDIT questionnaire.
  • Allergy to iodine
  • Thrombocytopenia, history of bleeding disorder or use of anticoagulation

Inclusion Criteria - Lean subjects without Diabetes:

-Subjects who do not have type 2 diabetes but are age and sex but are not weight-matched (BMI ≤ 25 Kg/M2) with subjects who have T2DM

Exclusion Criteria - Lean subjects without Diabetes:

  • Age \< 25 or > 65 years (match subjects with T2DM)
  • HbA1c ≥ 6.5%
  • BMI ≥ 25 Kg/M2 unless % body fat is \< 20% in males and \< 30% in females.
  • Use of any glucose-lowering agents
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.
  • Known contraindications to MRI
  • Hematocrit \< 35%
  • History of uncontrolled thyroid disease.
  • Consumption of > 2 alcohol drinks per day or > 14 per week or a positive AUDIT questionnaire.
  • Liver fat content ≥ 5% as determined by MRI using the proton density fat fraction (PDFF) technique.
  • Allergy to iodine
  • Thrombocytopenia, history of bleeding disorder or use of anticoagulation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Healthy Adults

    We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.

    Drug: Glucagon response study

  • Experimental
    Obese Adults Protein Density Fat Fraction (PDFF) < 5%

    We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.

    Drug: Glucagon response study

  • Experimental
    Adults with Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%

    We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.

    Drug: Glucagon response study

  • Experimental
    Adults with Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%

    We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.

    Drug: Glucagon response study

  • Experimental
    Obese Adults Protein Density Fat Fraction (PDFF) > 5%

    We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.

    Drug: Glucagon response study

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of Amino Acid Catabolism in the Presence / Absence of Glucagon

    Amino acid catabolism assessed by leucine reamination, a surrogate measure of leucine oxidation, during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes).

    Time frame: 0 minutes, 120 minutes, 240 minutes

Secondary outcomes

  1. Effect of Diabetes on Amino-acid Catabolism

    Tracer-dependent measurement of amino-acid clearance

    Time frame: 240 minutes of study

  2. Splanchnic Balance of Essential Amino Acids During Fasting and Glucagon Infusion

    Splanchnic balance of essential amino acids calculated from the arteriovenous concentration difference across the liver multiplied by splanchnic blood flow. Measurements were obtained during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes) to evaluate the effect of obesity and hepatic steatosis on glucagon-mediated amino acid metabolism.

    Time frame: 0 Minutes, 120 Minutes, 240 Minutes

  3. Splanchnic Balance of Nonessential Amino Acids During Fasting and Glucagon Infusion

    Splanchnic balance of nonessential amino acids calculated from the arteriovenous concentration difference across the liver multiplied by splanchnic blood flow. Measurements were obtained during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes) to evaluate the effect of obesity and hepatic steatosis on glucagon-mediated amino acid metabolism.

    Time frame: 0 Minutes, 120 Minutes, 240 Minutes

07

Results

Posted Oct 14, 2026

Participant flow

Participant flow — Overall Study
MilestoneHealthy AdultsObese Adults Protein Density Fat Fraction (PDFF) < 5%Obese Subjects Protein Density Fat Fraction (PDFF) > 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%
Started76700
Completed76700
Not completed00000

Outcome measures

PrimaryRate of Amino Acid Catabolism in the Presence / Absence of Glucagon

Amino acid catabolism assessed by leucine reamination, a surrogate measure of leucine oxidation, during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes).

Time frame:
0 minutes, 120 minutes, 240 minutes
Reported as:
Mean · mmol/min
Rate of Amino Acid Catabolism in the Presence / Absence of Glucagon
mmol/minHealthy AdultsObese Adults Protein Density Fat Fraction (PDFF) < 5%Obese Subjects Protein Density Fat Fraction (PDFF) > 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%
Fasting (0 Minutes)17 ± 226 ± 520 ± 6——
Intermediate Glucagon Infusion (120 Minutes)12 ± 119 ± 222 ± 7——
High Glucagon Infusion (240 Minutes)10 ± 116 ± 214 ± 4——
SecondaryEffect of Diabetes on Amino-acid Catabolism

Tracer-dependent measurement of amino-acid clearance

Time frame:
240 minutes of study

No measurements were reported for this outcome.

SecondarySplanchnic Balance of Essential Amino Acids During Fasting and Glucagon Infusion

Splanchnic balance of essential amino acids calculated from the arteriovenous concentration difference across the liver multiplied by splanchnic blood flow. Measurements were obtained during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes) to evaluate the effect of obesity and hepatic steatosis on glucagon-mediated amino acid metabolism.

Time frame:
0 Minutes, 120 Minutes, 240 Minutes
Reported as:
Mean · nmol/min
Splanchnic Balance of Essential Amino Acids During Fasting and Glucagon Infusion
nmol/minHealthy AdultsObese Adults Protein Density Fat Fraction (PDFF) < 5%Obese Subjects Protein Density Fat Fraction (PDFF) > 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%
Valine 0 Minutes1.1 ± 5.32.0 ± 2.30.5 ± 3.0——
Valine 120 Minutes4.0 ± 2.36.4 ± 1.13.9 ± 2.1——
Valine 240 Minutes4.7 ± 0.93.6 ± 1.36.4 ± 1.7——
Isoleucine 0 Minutes0.1 ± 1.40.6 ± 0.4-0.3 ± 1.0——
Isoleucine 120 Minutes2.4 ± 0.63.5 ± 0.72.0 ± 0.5——
Isoleucine 240 Minutes2.2 ± 0.31.8 ± 0.32.6 ± 0.5——
Leucine 0 Minutes0.1 ± 3.41.6 ± 1.20.1 ± 2.1——
Leucine 120 Minutes3.8 ± 1.35.2 ± 1.13.1 ± 1.1——
Leucine 240 Minutes4.1 ± 0.52.4 ± 0.64.2 ± 1.1——
Phenylalanine 0 Minutes1.9 ± 1.23.4 ± 0.61.2 ± 1.1——
Phenylalanine 120 Minutes4.1 ± 0.86.3 ± 0.53.6 ± 1.0——
Phenylalanine 240 Minutes5.2 ± 0.45.8 ± 0.54.6 ± 1.3——
Tryptophan 0 Minutes0.7 ± 1.42.1 ± 0.40.5 ± 0.9——
Tryptophan 120 Minutes1.2 ± 0.72.6 ± 0.41.6 ± 0.7——
Tryptophan 240 Minutes2.0 ± 0.22.3 ± 0.82.1 ± 0.6——
Tyrosine 0 Minutes4.2 ± 1.37.9 ± 0.92.9 ± 1.8——
Tyrosine 120 Minutes3.7 ± 0.56.4 ± 0.32.8 ± 1.3——
Tyrosine 240 Minutes3.1 ± 0.34.0 ± 0.42.9 ± 1.2——
Methionine 0 Minutes1.7 ± 0.53.0 ± 0.40.8 ± 0.7——
Methionine 120 Minutes4.2 ± 0.56.3 ± 0.33.1 ± 0.9——
Methionine 240 Minutes4.8 ± 0.46.6 ± 0.63.9 ± 1.2——
Cysteine 0 Minutes0.3 ± 0.8-0.4 ± 0.80.0 ± 0.6——
Cysteine 120 Minutes-0.1 ± 0.41.3 ± 0.3-0.4 ± 0.6——
Cysteine 240 Minutes0.5 ± 0.3-0.7 ± 1.40.9 ± 0.6——
Histidine 0 Minutes1.2 ± 4.72.8 ± 1.02.4 ± 3.4——
Histidine 120 Minutes7.1 ± 2.511.2 ± 2.38.1 ± 1.2——
Histidine 240 Minutes10.9 ± 1.211.7 ± 2.310.5 ± 1.6——
Lysine 0 Minutes5.9 ± 3.610.5 ± 3.23.4 ± 4.3——
Lysine 120 Minutes7.1 ± 1.912.1 ± 1.86.5 ± 2.6——
Lysine 240 Minutes8.8 ± 0.88.7 ± 1.79.6 ± 2.3——
Proline 0 Minutes0.6 ± 4.65.2 ± 1.81.5 ± 3.5——
Proline 120 Minutes6.9 ± 1.810.2 ± 1.26.4 ± 2.0——
Proline 240 Minutes9.4 ± 0.89.5 ± 0.88.8 ± 2.2——
Threonine 0 Minutes7.2 ± 2.611.6 ± 1.93.6 ± 3.1——
Threonine 120 Minutes9.4 ± 1.113.8 ± 1.06.7 ± 2.4——
Threonine 240 Minutes10.2 ± 0.711.8 ± 1.18.1 ± 2.5——
SecondarySplanchnic Balance of Nonessential Amino Acids During Fasting and Glucagon Infusion

Splanchnic balance of nonessential amino acids calculated from the arteriovenous concentration difference across the liver multiplied by splanchnic blood flow. Measurements were obtained during fasting (0 minutes), intermediate glucagon infusion (120 minutes), and high glucagon infusion (240 minutes) to evaluate the effect of obesity and hepatic steatosis on glucagon-mediated amino acid metabolism.

Time frame:
0 Minutes, 120 Minutes, 240 Minutes
Reported as:
Mean · nmol/min
Splanchnic Balance of Nonessential Amino Acids During Fasting and Glucagon Infusion
nmol/minHealthy AdultsObese Adults Protein Density Fat Fraction (PDFF) < 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%Obese Adults Protein Density Fat Fraction (PDFF) > 5%
Glycine 0 Minutes-2.1 ± 9.013.8 ± 4.55.7 ± 4.8——
Glycine 120 Minutes-1.9 ± 5.118.0 ± 4.111.7 ± 2.1——
Glycine 240 Minutes6.9 ± 2.220.8 ± 4.215.9 ± 2.5——
Alanine 0 Minutes43.1 ± 5.582.9 ± 11.432.8 ± 20.9——
Alanine 120 Minutes50.5 ± 4.981.0 ± 6.537.7 ± 14.6——
Alanine 240 Minutes74.2 ± 8.999.5 ± 9.955.1 ± 20.6——
Asparagine 0 Minutes4.1 ± 1.76.3 ± 1.02.1 ± 1.5——
Asparagine 120 Minutes4.0 ± 0.65.3 ± 0.92.6 ± 1.1——
Asparagine 240 Minutes3.9 ± 0.33.5 ± 0.62.7 ± 0.9——
Arginine 0 Minutes5.9 ± 2.38.2 ± 1.71.8 ± 2.5——
Arginine 120 Minutes11.3 ± 1.711.9 ± 0.75.1 ± 1.7——
Arginine 240 Minutes12.3 ± 1.111.1 ± 1.06.8 ± 1.5——
Glutamine 0 Minutes17.0 ± 16.035.6 ± 5.810.5 ± 10.3——
Glutamine 120 Minutes16.4 ± 5.936.0 ± 4.619.1 ± 4.8——
Glutamine 240 Minutes25.3 ± 4.027.2 ± 3.023.0 ± 5.8——
Glutamic Acid 0 Minutes-30.2 ± 4.3-59.1 ± 5.8-29.0 ± 11.1——
Glutamic Acid 120 Minutes-25.7 ± 2.8-46.1 ± 3.3-21.0 ± 11.2——
Glutamic Acid 240 Minutes-25.0 ± 3.3-45.5 ± 5.2-20.9 ± 10.7——
Aspartic Acid 0 Minutes-0.5 ± 0.1-0.6 ± 0.2-0.5 ± 0.3——
Aspartic Acid 120 Minutes0.5 ± 0.20.3 ± 0.20.3 ± 0.1——
Aspartic Acid 240 Minutes0.5 ± 0.20.3 ± 0.10.3 ± 0.1——
Serine 0 Minutes8.0 ± 3.712.2 ± 2.03.6 ± 2.8——
Serine 120 Minutes14.8 ± 2.119.5 ± 1.18.9 ± 3.2——
Serine 240 Minutes16.3 ± 2.019.4 ± 3.410.7 ± 3.2——

Adverse events

Collected over Adverse events were collected from the time of informed consent through study completion, approximately 4 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Adults0/7 (0%)0/7 (0%)6/7 (85.7%)
Obese Adults Protein Density Fat Fraction (PDFF) < 5%0/6 (0%)0/6 (0%)6/6 (100%)
Obese Adults Protein Density Fat Fraction (PDFF) > 5%0/7 (0%)0/7 (0%)6/7 (85.7%)
Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%———
Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%———
Most frequent other events
Showing 10 of 12
Most frequent other events
EventHealthy AdultsObese Adults Protein Density Fat Fraction (PDFF) < 5%Obese Adults Protein Density Fat Fraction (PDFF) > 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%
Femoral Site Bruising/TendernessInjury, poisoning and procedural complications4/74/63/7——
Back PainMusculoskeletal and connective tissue disorders3/73/64/7——
IV Site Bruising/TendernessInjury, poisoning and procedural complications3/71/62/7——
NauseaGastrointestinal disorders3/71/61/7——
HypotensionVascular disorders1/72/62/7——
General AchingGeneral disorders0/70/62/7——
DiarrheaGastrointestinal disorders1/70/60/7——
GI Upset, Feeling WarmGastrointestinal disorders1/70/60/7——
HeadacheNervous system disorders1/70/61/7——
Leg DiscomfortGeneral disorders1/70/60/7——

Baseline characteristics

0 subjects with Type 2 Diabetes were enrolled due to a lack of interest in participation.

Age, Continuous
Age, Continuous(years)Healthy AdultsObese Adults Protein Density Fat Fraction (PDFF) < 5%Obese Adults Protein Density Fat Fraction (PDFF) > 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%Total
Mean38 ± 452 ± 546 ± 5——44.7 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Healthy AdultsObese Adults Protein Density Fat Fraction (PDFF) < 5%Obese Adults Protein Density Fat Fraction (PDFF) > 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%Total
Female737——17
Male030——3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Healthy AdultsObese Adults Protein Density Fat Fraction (PDFF) < 5%Obese Adults Protein Density Fat Fraction (PDFF) > 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%Total
Hispanic or Latino000——0
Not Hispanic or Latino767——20
Unknown or Not Reported000——0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healthy AdultsObese Adults Protein Density Fat Fraction (PDFF) < 5%Obese Adults Protein Density Fat Fraction (PDFF) > 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%Total
American Indian or Alaska Native000——0
Asian000——0
Native Hawaiian or Other Pacific Islander000——0
Black or African American001——1
White766——19
More than one race000——0
Unknown or Not Reported000——0
Region of Enrollment
Region of Enrollment(participants)Healthy AdultsObese Adults Protein Density Fat Fraction (PDFF) < 5%Obese Adults Protein Density Fat Fraction (PDFF) > 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%Adults With Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%Total
United States767——20
08

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No plan

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Sep 2025, 35 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 39 non-industry phase 1/2 interventional studies under Obesity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 35 months is above that.

Counting every sponsor, half of 62 studies reached it within 27 months; a quarter within 14 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2022
First posted
Aug 15, 2022
StartActual
Oct 20, 2022
Primary completionActual
Sep 30, 2025
CompletionActual
Mar 31, 2026
Results first posted
Oct 14, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 14, 2026
Eligibility
Criteria largely rewritten (55 changes)
What changed in the criteria
  • AddedInclusion Criteria - Obese Subjects with Type 2 Diabetes:
  • AddedType 2 diabetes
  • AddedBMI ≥ 28 Kg/M2
  • AddedManaged by diet alone or a combination of metformin and/or sulfonylurea
  • AddedWilling to stop glucose-lowering medication for 3 weeks prior to participation and willing to self-monitor their fasting glucose during this time
  • AddedNo history of micro- or macrovascular complications of T2DM
  • AddedExclusion Criteria - Obese Subjects with Type 2 Diabetes:
  • AddedAge < 25 or > 65 years
  • AddedHbA1c ≥ 8.5%
  • AddedBMI ≤ 28 Kg/M2
  • AddedFor female subjects: positive pregnancy test at the time of enrollment or study
  • EditedHistory of prior upper abdominal surgery e.g.such as adjustable gastric banding, pyloroplasty, and vagotomy.
  • ChangedBefore Contraindications to MRI (e.g. metal implants, claustrophobia).Now Known contraindications to MRI
  • AddedHistory of uncontrolled thyroid disease
  • AddedAllergy to iodine
  • AddedThrombocytopenia, history of bleeding disorder or use of anticoagulation
  • AddedSubjects with treatment change or significant weight change (≥ 10%) in the prior 3 months.
  • AddedInclusion Criteria - Obese subjects without Type 2 Diabetes:
  • Added-Obese subjects without type 2 diabetes but are age, sex and weight-matched (BMI ≥ 28 Kg/M2) with subjects who have T2DM
  • AddedExclusion Criteria - Obese Subjects without Type 2 Diabetes:
  • AddedAge < 25 or > 65 years (match subjects with T2DM)
  • AddedHbA1c ≥ 6.5%
  • AddedBMI ≤ 28 Kg/M2
  • AddedUse of any glucose-lowering agents
  • AddedFor female subjects: positive pregnancy test at the time of enrollment or study
  • AddedHistory of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • AddedActive systemic illness or malignancy.
  • AddedSymptomatic macrovascular or microvascular disease.
  • AddedKnown contraindications to MRI
  • AddedHematocrit < 35%
  • AddedHistory of uncontrolled thyroid disease.
  • AddedConsumption of > 2 alcohol drinks per day or > 14 per week or a positive AUDIT questionnaire.
  • AddedAllergy to iodine
  • AddedThrombocytopenia, history of bleeding disorder or use of anticoagulation
  • AddedInclusion Criteria - Lean subjects without Diabetes:
  • Added-Subjects who do not have type 2 diabetes but are age and sex but are not weight-matched (BMI ≤ 25 Kg/M2) with subjects who have T2DM
  • AddedExclusion Criteria - Lean subjects without Diabetes:
  • AddedAge < 25 or > 65 years (match subjects with T2DM)
  • AddedHbA1c ≥ 6.5%
  • AddedBMI ≥ 25 Kg/M2 unless % body fat is < 20% in males and < 30% in females.

…and 15 more changes, on the record history on ClinicalTrials.gov ↗

Oct 14, 2026
Interventions
Arms added: Obese Adults Protein Density Fat Fraction (PDFF) < 5%·Adults with Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%·Adults with Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%·Obese Adults Protein Density Fat Fraction (PDFF) > 5%; arms removed: Obese Adults·Adults with Type 2 Diabetes
Oct 14, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRate of Amino acid catabolismAcid Catabolism in the presencePresence / absenceAbsence of glucagonGlucagonTime frame: 240 minutes of study → 0 minutes, 120 minutes, 240 minutes
Oct 14, 2026
Documents
Secondary outcomes
1 edited, 2 added
What changed in the outcomes
  • EditedEffect of Diabetes on aminoAmino-acid catabolismCatabolismTime frame: 240 minutes of study
  • AddedSplanchnic Balance of Essential Amino Acids During Fasting and Glucagon InfusionTime frame: 0 Minutes, 120 Minutes, 240 Minutes
  • AddedSplanchnic Balance of Nonessential Amino Acids During Fasting and Glucagon InfusionTime frame: 0 Minutes, 120 Minutes, 240 Minutes
Oct 14, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 14, 2026
    Results posted
    Eligibility Criteria largely rewritten (55 changes)
    What changed in the criteria
    • AddedInclusion Criteria - Obese Subjects with Type 2 Diabetes:
    • AddedType 2 diabetes
    • AddedBMI ≥ 28 Kg/M2
    • AddedManaged by diet alone or a combination of metformin and/or sulfonylurea
    • AddedWilling to stop glucose-lowering medication for 3 weeks prior to participation and willing to self-monitor their fasting glucose during this time
    • AddedNo history of micro- or macrovascular complications of T2DM
    • AddedExclusion Criteria - Obese Subjects with Type 2 Diabetes:
    • AddedAge < 25 or > 65 years
    • AddedHbA1c ≥ 8.5%
    • AddedBMI ≤ 28 Kg/M2
    • AddedFor female subjects: positive pregnancy test at the time of enrollment or study
    • EditedHistory of prior upper abdominal surgery e.g.such as adjustable gastric banding, pyloroplasty, and vagotomy.
    • ChangedBefore Contraindications to MRI (e.g. metal implants, claustrophobia).Now Known contraindications to MRI
    • AddedHistory of uncontrolled thyroid disease
    • AddedAllergy to iodine
    • AddedThrombocytopenia, history of bleeding disorder or use of anticoagulation
    • AddedSubjects with treatment change or significant weight change (≥ 10%) in the prior 3 months.
    • AddedInclusion Criteria - Obese subjects without Type 2 Diabetes:
    • Added-Obese subjects without type 2 diabetes but are age, sex and weight-matched (BMI ≥ 28 Kg/M2) with subjects who have T2DM
    • AddedExclusion Criteria - Obese Subjects without Type 2 Diabetes:
    • AddedAge < 25 or > 65 years (match subjects with T2DM)
    • AddedHbA1c ≥ 6.5%
    • AddedBMI ≤ 28 Kg/M2
    • AddedUse of any glucose-lowering agents
    • AddedFor female subjects: positive pregnancy test at the time of enrollment or study
    • AddedHistory of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
    • AddedActive systemic illness or malignancy.
    • AddedSymptomatic macrovascular or microvascular disease.
    • AddedKnown contraindications to MRI
    • AddedHematocrit < 35%
    • AddedHistory of uncontrolled thyroid disease.
    • AddedConsumption of > 2 alcohol drinks per day or > 14 per week or a positive AUDIT questionnaire.
    • AddedAllergy to iodine
    • AddedThrombocytopenia, history of bleeding disorder or use of anticoagulation
    • AddedInclusion Criteria - Lean subjects without Diabetes:
    • Added-Subjects who do not have type 2 diabetes but are age and sex but are not weight-matched (BMI ≤ 25 Kg/M2) with subjects who have T2DM
    • AddedExclusion Criteria - Lean subjects without Diabetes:
    • AddedAge < 25 or > 65 years (match subjects with T2DM)
    • AddedHbA1c ≥ 6.5%
    • AddedBMI ≥ 25 Kg/M2 unless % body fat is < 20% in males and < 30% in females.

    …and 15 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRate of Amino acid catabolismAcid Catabolism in the presencePresence / absenceAbsence of glucagonGlucagonTime frame: 240 minutes of study → 0 minutes, 120 minutes, 240 minutes
    Secondary outcomes 1 edited, 2 added
    What changed in the outcomes
    • EditedEffect of Diabetes on aminoAmino-acid catabolismCatabolismTime frame: 240 minutes of study
    • AddedSplanchnic Balance of Essential Amino Acids During Fasting and Glucagon InfusionTime frame: 0 Minutes, 120 Minutes, 240 Minutes
    • AddedSplanchnic Balance of Nonessential Amino Acids During Fasting and Glucagon InfusionTime frame: 0 Minutes, 120 Minutes, 240 Minutes
    Interventions Arms added: Obese Adults Protein Density Fat Fraction (PDFF) < 5%·Adults with Type 2 Diabetes Protein Density Fat Fraction (PDFF) < 5%·Adults with Type 2 Diabetes Protein Density Fat Fraction (PDFF) > 5%·Obese Adults Protein Density Fat Fraction (PDFF) > 5%; arms removed: Obese Adults·Adults with Type 2 Diabetes
    + 4 other changes: identifiers, verification date, responsible party and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05500586
Lead sponsor
Adrian Vella
Responsible party
Adrian Vella (Regulatory Sponsor, Mayo Clinic) — Sponsor-investigator
First posted
Aug 15, 2022
Start date
Oct 20, 2022
Primary completion
Sep 30, 2025
Completion
Mar 31, 2026
Results posted
Oct 14, 2026
Last update
Nov 4, 2026

Study contacts

Adrian Vella
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glucagon

Start the discussion